Live moderated video webcast discussion with President, CEO and CFO Lawrence Kenyon, on Wednesday, June 17th at 2:00 PM ET, immediately followed by an interactive Q&A session MONMOUTH JUNCTION, N.J. , June 09, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.

MONMOUTH JUNCTION, N.J. , June 03, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the

Strategic investment at a premium enhances Company’s ongoing development activities of ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab to treat wet AMD, toward FDA approval   Syntone and Outlook to form joint venture to develop and commercialize

Company remains on track to report topline data results from NORSE 1, its first registration clinical trial evaluating ONS-5010, an investigational ophthalmic formulation of bevacizumab to treat wet AMD, in August 2020   Enrollment in NORSE 2 registration clinical trial remains ongoing and is

Internationally renowned ophthalmologist, Gerd Auffarth , MD, ranked as one of the “100 most influential personalities in ophthalmology worldwide" in the 2020 Power List published by The Ophthalmologist  magazine Julian Gangolli , former President of the North American Pharmaceutical division of

Presentation with live audio webcast on Wednesday, April 22 at 10:30 AM ET, immediately followed by an interactive Q&A session CRANBURY, N.J. , April 15, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to

Company reports no anticipated COVID-19 impact on NORSE 1, its first registration clinical trial evaluating ONS-5010, an investigational ophthalmic formulation of bevacizumab, to treat wet AMD   Risk mitigation strategies being developed for possible one- to three-month delay related to COVID-19

Outlook Therapeutics intends to market ONS-5010 as LYTENAVA ™  (bevacizumab-vikg), if approved. LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for retinal indications, is currently in two registration clinical trials (NORSE 1 and NORSE 2) to treat wet

CRANBURY, N.J. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has

CRANBURY, N.J. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has